Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.04.009Source: DataRank Database

Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients is a research paper published in Journal of Cystic Fibrosis (2022). On theSindex it has a DataRank of 0. It has been cited 47 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access47 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 5.59)OA: greenTopics (66)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Jennifer S. Guimbellot ORCID,Maryam Valapour ORCID,Lauren Bartlett ORCID,Travis Hee Wai ORCID,Christopher H. Goss ORCID

Live enrichment

PubMed:35474016 PMC:PMC9509406 OpenAlex:https://openalex.org/W4224982000

National Institutes of Health

Grant: K23HL138154

Cystic Fibrosis Foundation

Grant: RAMOS17A0

Cystic Fibrosis Foundation

Grant: LEASE16A3

NIDDK NIH HHS

Grant: P30 DK089507

NHLBI NIH HHS

Grant: K23 HL143167

NIDDK NIH HHS

Grant: P30 DK072482

National Institutes of Health

Grant: 5K23HL138154-02

Predicting survival and planning for lung transplantation in severe cystic fibrosis

CHEST Foundation

Cystic Fibrosis Foundation

FWCI

5.59

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier Non-Commercial

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9509406

publisherhttps://api.elsevier.com/content/article/PII:S1569199322000984?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199322000984?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2022.04.009

Fields of Study

Cystic Fibrosis Research AdvancesTransplantation: Methods and OutcomesComplement system in diseases03 medical and health sciences0302 clinical medicineAminophenolsBenzodioxolesChloride Channel AgonistsCohort StudiesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorGlycated HemoglobinHumansIndolesLungMutationPyrazolesPyridinesPyrrolidinesQuinolonesTransaminasesTransplant Recipients

MeSH Terms

AminophenolsTransaminasesCystic FibrosisGlycated HemoglobinHumansIndolesLungMutationPyrazolesPyridinesPyrrolidinesCohort StudiesQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesChloride Channel AgonistsTransplant Recipients

Keywords

MedicineIvacaftorCystic fibrosisInternal medicineBody mass indexDiscontinuationPopulationHemoglobinGastroenterologyCystic fibrosis transmembrane conductance regulatorLung transplantationTrikaftaGlycated HemoglobinIndolesPyrrolidinesPyridinesQuinolonesAminophenolsTransplant RecipientsCohort StudiesMutationHumansPyrazolesBenzodioxolesChloride Channel AgonistsLungTransaminases

Sustainable Development Goals

SDG 0: Good health and well-being